Valuation: Definium Therapeutics, Inc.

Market Cap 4.02B 3.65B 3.37B 3.04B 5.75B 376B 5.97B 40.65B 16.08B 203B 15.09B 14.78B 641B P/E 2026 *
-9.96x
P/E 2027 * -15x
Enterprise Value 3.05B 2.77B 2.56B 2.31B 4.36B 285B 4.53B 30.87B 12.21B 154B 11.46B 11.22B 487B EV / Sales 2026 *
-
EV / Sales 2027 * 111x
Free-Float
96.8%
Yield 2026 *
-
Yield 2027 * -
1 day-2.59%
1 week-16.98%
Current month-19.13%
1 month-8.47%
3 months-31.08%
6 months+39.97%
Current year+119.42%
1 week 28.44
Extreme 28.44
35.23
1 month 28.44
Extreme 28.44
39.14
Current year 12.88
Extreme 12.882
49.7
1 year 10.46
Extreme 10.4646
49.7
3 years 2.54
Extreme 2.54
49.7
5 years 2.12
Extreme 2.12
49.7
10 years 1.25
Extreme 1.249499
86.55
Manager TitleAgeSince
Chief Executive Officer 37 2021-06-08
Director of Finance/CFO 52 2025-06-01
Chief Tech/Sci/R&D Officer 46 2021-01-31
Director TitleAgeSince
Director/Board Member 37 2021-12-12
Director/Board Member 67 2021-09-28
Chairman 69 2021-12-12
Date Insider Type Main position Quantity % Market Cap. Importance
9/25/26 Sell

General Counsel

-14,051 0.0106%
9/25/26 Sell

Chief Technology Officer

-10,853 0.0082%
9/25/26 Sell

Executive/Senior Manager

-3,097 0.0023%
Change 5-day change 1-year change 3-year change Capi.($)
-2.59%-16.98%+158.85%+1,094.31% 4.13B
+1.15%-2.81%+53.73%+71.00% 65.56B
-2.64%+0.07%+9.57%+89.87% 60.41B
-1.07%+0.55%+21.79%+87.66% 55.76B
+0.48%-0.98%+12.97%+118.46% 46.98B
-2.69%-7.62%+16.77%+25.79% 43.63B
-0.70%+1.43%+14.05%+45.20% 36.7B
-2.50%-18.72%+140.13%+665.60% 36.09B
-0.77%-4.34%+79.27%+59.47% 32.9B
-0.83%+4.96%-36.93%+398.61% 26.96B
Average -1.22%-3.01%+47.02%+265.60% 41B
Weighted average by Cap. -1.01%-1.62%+35.44%+157.81%

Financials

2026 *2027 *
Net sales - 29.35M 26.64M 24.61M 22.2M 41.91M 2.74B 43.52M 297M 117M 1.48B 110M 108M 4.67B
Net income -356M -323M -298M -269M -508M -33.26B -528M -3.6B -1.42B -17.95B -1.34B -1.31B -56.7B -280M -254M -235M -212M -399M -26.13B -415M -2.83B -1.12B -14.1B -1.05B -1.03B -44.55B
Net Debt -968M -879M -812M -733M -1.38B -90.47B -1.44B -9.78B -3.87B -48.82B -3.63B -3.56B -154B -761M -691M -638M -576M -1.09B -71.1B -1.13B -7.69B -3.04B -38.37B -2.86B -2.8B -121B
Projected Income Statement - Annual - Definium Therapeutics, Inc.
Logo Definium Therapeutics, Inc.
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
Employees
-
Date Price Change Volume
26-11-17 US$29.39 -2.57% 1,923,837
26-11-16 US$30.16 -5.99% 1,131,914
26-11-13 US$32.08 -2.79% 778,187
26-11-12 US$33.00 -4.26% 1,202,803
26-11-11 US$34.47 -0.49% 1,441,543
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Definium Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
29.38USD
Average target price
72.83USD
Spread / Average Target
+147.86%
  1. Stock Market
  2. Stocks
  3. DFTX Stock